HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Douglas J. Mathisen John C. Wain Cameron Wright Hermes Grillo Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mathisen, D. J. Articles by Grillo, H. Search for Related Content PubMed PubMed Citation Articles by Mathisen, D. J. Articles by Grillo, H.

J Thorac Cardiovasc Surg 1996;111:123-133
© 1996 Mosby, Inc.

GENERAL THORACIC SURGERY

ASSESSMENT OF PREOPERATIVE ACCELERATED RADIOTHERAPY AND CHEMOTHERAPY IN STAGE IIIA (N2) NON-SMALL-CELL LUNG CANCER

Boston, Mass.

From the Section of General Thoracic Surgery, Massachusetts General Hospital, Boston, Mass.

Address for reprints: Douglas J. Mathisen, MD, Chief, General Thoracic Surgery, Massachusetts General Hospital, Warren 1109, Boston, MA 02114.

Abstract

Forty patients with N2 non-small-cell lung cancer (stage IIIA), as determined by mediastinoscopy, were entered into a preoperative neoadjuvant study of chemotherapy (platinum, 5-fluorouracil, vinblastine) and accelerated radiotherapy (150 cGy twice per day for 7 days) for two cycles. Surgical resection was then performed and followed up with an additional cycle of chemotherapy and radiotherapy. All patients completed preoperative therapy. A major clinical response was seen in 87% of patients. Thirty-five patients underwent resection (one preoperative death, one refused operation, one had deterioration of pulmonary function, and two had pleural metastases). Operative mortality rate was 5.7% (2/35). Sixty percent of patients had no complications. Major complications included pulmonary emboli (three), pneumonia (two), and myocardial infarction (one). Downstaging was seen in 46% of patients, with two patients (5.7%) having no evidence of tumor in the specimen, five patients having sterilization of all lymph nodes, and nine patients having sterilization of mediastinal nodes but positive N1 nodes. Median survival of 40 patients was 28 months, with a projected 5-year survival of 43%. Patients with downstaged disease had statistically significant improved survival compared with patients whose disease was not downstaged. (J THORAC CARDIOVASC SURG 1996;111:123-33)

This article has been cited by other articles:

				R. J. Cerfolio, A. S. Bryant, and M. Yamamuro Intercostal Muscle Flap to Buttress the Bronchus at Risk and the Thoracic Esophageal-Gastric Anastomosis Ann. Thorac. Surg., September 1, 2005; 80(3): 1017 - 1020. [Abstract] [Full Text] [PDF]

				K. Okubo, T. Kato, A. Hara, N. Yoshimi, K. Takeda, and F. Iwao Imprint Cytology for Detecting Metastasis of Lung Cancer in Mediastinal Lymph Nodes Ann. Thorac. Surg., October 1, 2004; 78(4): 1190 - 1193. [Abstract] [Full Text] [PDF]

				B. H. Kwek, J. C. Wain, and S. L. Aquino The radiologic appearance of intercostal muscle flap Ann. Thorac. Surg., August 1, 2004; 78(2): 432 - 435. [Abstract] [Full Text] [PDF]

				K. Okubo, J. Isobe, T. Sato, and Y. Ueno Cotton-type collagen insertion at mediastinoscopy for easier node dissection after induction chemoradiotherapy for lung cancer J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1532 - 1533. [Full Text] [PDF]

				M. K. Ferguson Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1935 - 1942. [Abstract] [Full Text] [PDF]

				Y. S. Choi, Y. M. Shim, J. Kim, and K. Kim Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer Eur. J. Cardiothorac. Surg., November 1, 2002; 22(5): 695 - 700. [Abstract] [Full Text] [PDF]

				G. Stamatis, D. Djuric, W. Eberhardt, C. Pottken, G. Zaboura, S. Fechner, and T. Fujimoto Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients Eur. J. Cardiothorac. Surg., August 1, 2002; 22(2): 292 - 297. [Abstract] [Full Text] [PDF]

				L. Voltolini, L. Luzzi, C. Ghiribelli, P. Paladini, M. Di Bisceglie, and G. Gotti Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1106 - 1112. [Abstract] [Full Text] [PDF]

				C. Doddoli, P. Thomas, X. Thirion, Y. Seree, R. Giudicelli, and P. Fuentes Postoperative complications in relation with induction therapy for lung cancer Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 385 - 390. [Abstract] [Full Text] [PDF]

				S. Margaritora, A. Cesario, D. Galetta, A. D'Andrilli, G. Macis, G. Mantini, L. Trodella, and P. Granone Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging? Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 894 - 898. [Abstract] [Full Text] [PDF]

				M. E. Deeb, D. H. Sterman, J. B. Shrager, and L. R. Kaiser Bronchial anastomotic stricture caused by ossification of an intercostal muscle flap Ann. Thorac. Surg., May 1, 2001; 71(5): 1700 - 1702. [Abstract] [Full Text] [PDF]

				M. Okada, N. Tsubota, M. Yoshimura, Y. Miyamoto, and H. Matsuoka Induction Therapy for Non-small Cell Lung Cancer With Involved Mediastinal Nodes in Multiple Stations Chest, July 1, 2000; 118(1): 123 - 128. [Abstract] [Full Text] [PDF]

				J. R. Sonett, M. J. Krasna, M. Suntharalingam, J. Schuetz, L. A. Doyle, R. Lilenbaum, and Z. Gamliel Safe pulmonary resection after chemotherapy and high-dose thoracic radiation Ann. Thorac. Surg., August 1, 1999; 68(2): 316 - 320. [Abstract] [Full Text] [PDF]

				K. Suzuki, K. Nagai, J. Yoshida, M. Nishimura, K. Takahashi, and Y. Nishiwaki THE PROGNOSIS OF SURGICALLY RESECTED N2 NON-SMALL CELL LUNGCANCER: THE IMPORTANCE OF CLINICAL N STATUS J. Thorac. Cardiovasc. Surg., July 1, 1999; 118(1): 145 - 153. [Abstract] [Full Text] [PDF]

				P. De Leyn, J. Vansteenkiste, G. Deneffe, D. Van Raemdonck, W. Coosemans, and T. Lerut Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy Eur. J. Cardiothorac. Surg., May 1, 1999; 15(5): 608 - 614. [Abstract] [Full Text] [PDF]

				J. Vansteenkiste, P. De Leyn, G. Deneffe, J. Menten, T. Lerut, and M. Demedts Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review Eur. J. Cardiothorac. Surg., January 1, 1998; 13(1): 1 - 12. [Abstract] [Full Text] [PDF]